Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

2(50.0%)

N/A

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 2(2)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT01879657Not ApplicableCompleted

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Role: collaborator

NCT00442533Phase 2Completed

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Role: collaborator

NCT05785663Completed

AminoMedixTM for Kidney Protection During Radionuclide Therapy

Role: collaborator

NCT03673943Phase 3Completed

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Role: lead

NCT02282137Phase 2Unknown

68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

Role: collaborator

All 5 trials loaded